Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 6Phase 1 6Phase 1/2 3Phase 4 1

Status

Completed 3Withdrawn 2Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 4Dermatologic 2Thoracic 1Other hematologic neoplasm 1

Conditions

Sezary Syndrome 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × 10-propargyl-10-deazaaminopterin × Clear all
NCT07036133 2026-02-11

SPI-FOL-102

Acrotech Biopharma Inc.

Phase 1 Recruiting
24 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT02594267 2021-07-27

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Acrotech Biopharma Inc.

Phase 1 Completed
48 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01789723 2020-01-23

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Acrotech Biopharma Inc.

Phase 1 Withdrawn
Lymphoid

Lymphoma, Non-Hodgkin

NCT01820091 2020-01-23

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Acrotech Biopharma Inc.

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00554827 2020-01-03

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
55 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡